The concept of using Mycobacterium for cancer treatment goes back to the 19th Century. Today, bacillus Calmette–Guerin (BCG) vaccine is a well-established treatment for human bladder cancer that ...
In this section, we will analyze the mechanisms attributed to BCG cancer immunotherapy for bladder cancer. Over 100 years ago, pathological studies unearthed an association between mycobacterial ...
Among patients with Bacillus Calmette-Guérin (BCG)-naïve, high-risk non-muscle invasive bladder cancer (NMIBC), treatment with the investigational anti-PD-1 monoclonal antibody sasanlimab, in ...
Anktiva (nogapendekin alfa inbakicep, or N-803) can be used in combination with the BCG vaccine in non-muscle invasive bladder cancer (NMIBC) patients who had not responded to the BCG shot on its ...
Pfizer chief oncology officer Roger Dansey said: “The initial therapy of high-risk, non-muscle invasive bladder cancer with BCG has not advanced in decades. Today’s pivotal Phase III CREST ...
1 “TAR-200 represents a novel interventional approach for the treatment of localized bladder cancer where today, unfortunately, options are limited and include antiquated BCG therapy or radical ...
Bladder cancer can be curable, and the likelihood of cure is higher if it is diagnosed at an early stage. Without treatment, bladder cancer does not go away on its own, and treatment is associated ...